![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-epigallocatechin 3-gallate | multiple interactions | ISO | RGD:1606144 | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF827 mRNA | CTD | PMID:22079256 | 1,2-dichloroethane | increases expression | ISO | RGD:1558203 | 6480464 | ethylene dichloride results in increased expression of ZFP827 mRNA | CTD | PMID:28960355 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1606144 | 6480464 | [Tetrachlorodibenzodioxin co-treated with 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide] results in decreased expression of ZNF827 mRNA | CTD | PMID:29704546 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ZFP827 mRNA | CTD | PMID:33387578 | 2,3,7,8-Tetrachlorodibenzofuran | decreases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | 3,4-methylenedioxymethamphetamine | increases expression | ISO | RGD:1558203 | 6480464 | N-Methyl-3, 4-methylenedioxyamphetamine results in increased expression of ZFP827 mRNA | CTD | PMID:20188158 | 4-hydroxyphenyl retinamide | increases expression | ISO | RGD:1558203 | 6480464 | Fenretinide results in increased expression of ZNF827 mRNA | CTD | PMID:28973697 | 5-aza-2'-deoxycytidine | affects expression | ISO | RGD:1606144 | 6480464 | Decitabine affects the expression of ZNF827 mRNA | CTD | PMID:23300844 | aflatoxin B1 | decreases methylation | ISO | RGD:1606144 | 6480464 | Aflatoxin B1 results in decreased methylation of ZNF827 exon, Aflatoxin B1 results in decreased methylation of ZNF827 gene | CTD | PMID:27153756, PMID:30157460 | all-trans-retinoic acid | increases expression | ISO | RGD:1606144 | 6480464 | Tretinoin results in increased expression of ZNF827 mRNA | CTD | PMID:21934132 | amphetamine | decreases expression | EXP | | 6480464 | Amphetamine results in decreased expression of ZFP827 mRNA | CTD | PMID:30779732 | antirheumatic drug | increases expression | ISO | RGD:1606144 | 6480464 | Antirheumatic Agents results in increased expression of ZNF827 mRNA | CTD | PMID:24449571 | aristolochic acid A | decreases expression | ISO | RGD:1606144 | 6480464 | aristolochic acid I results in decreased expression of ZNF827 mRNA | CTD | PMID:33212167 | arsane | affects methylation | ISO | RGD:1606144 | 6480464 | Arsenic affects the methylation of ZNF827 gene | CTD | PMID:25304211 | arsenic atom | affects methylation | ISO | RGD:1606144 | 6480464 | Arsenic affects the methylation of ZNF827 gene | CTD | PMID:25304211 | atrazine | affects methylation | EXP | | 6480464 | Atrazine affects the methylation of ZFP827 gene | CTD | PMID:28931070 | benzo[a]pyrene | decreases expression | ISO | RGD:1558203 | 6480464 | Benzo(a)pyrene results in decreased expression of ZFP827 mRNA | CTD | PMID:21569818 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of ZNF827 mRNA | CTD | PMID:25181051 | butanal | decreases expression | ISO | RGD:1606144 | 6480464 | butyraldehyde results in decreased expression of ZNF827 mRNA | CTD | PMID:26079696 | cadmium atom | multiple interactions | ISO | RGD:1606144 | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of ZNF827 mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | RGD:1606144 | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of ZNF827 mRNA | CTD | PMID:35301059 | caffeine | affects phosphorylation | ISO | RGD:1606144 | 6480464 | Caffeine affects the phosphorylation of ZNF827 protein | CTD | PMID:35688186 | chlordecone | increases expression | ISO | RGD:1558203 | 6480464 | Chlordecone results in increased expression of ZFP827 mRNA | CTD | PMID:33711761 | choline | multiple interactions | ISO | RGD:1558203 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ZFP827 gene | CTD | PMID:20938992 | chromium(6+) | decreases expression | ISO | RGD:1606144 | 6480464 | chromium hexavalent ion results in decreased expression of ZNF827 mRNA | CTD | PMID:30690063 | cisplatin | affects expression | ISO | RGD:1606144 | 6480464 | Cisplatin affects the expression of ZNF827 mRNA | CTD | PMID:23300844 | cisplatin | multiple interactions | ISO | RGD:1606144 | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of ZNF827 mRNA | CTD | PMID:27392435 | copper atom | increases expression | EXP | | 6480464 | Copper deficiency results in increased expression of ZFP827 mRNA | CTD | PMID:26033743 | copper(0) | increases expression | EXP | | 6480464 | Copper deficiency results in increased expression of ZFP827 mRNA | CTD | PMID:26033743 | crocidolite asbestos | decreases expression | ISO | RGD:1606144 | 6480464 | Asbestos, Crocidolite results in decreased expression of ZNF827 mRNA | CTD | PMID:29523930 | Cuprizon | increases expression | EXP | | 6480464 | Cuprizone results in increased expression of ZFP827 mRNA | CTD | PMID:26577399 | cyclophosphamide | increases expression | EXP | | 6480464 | Cyclophosphamide results in increased expression of ZFP827 mRNA | CTD | PMID:27281708 | dibutyl phthalate | decreases expression | ISO | RGD:1558203 | 6480464 | Dibutyl Phthalate results in decreased expression of ZFP827 mRNA | CTD | PMID:21266533 | dicrotophos | increases expression | ISO | RGD:1606144 | 6480464 | dicrotophos results in increased expression of ZNF827 mRNA | CTD | PMID:28302478 | dorsomorphin | multiple interactions | ISO | RGD:1606144 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF827 mRNA | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | RGD:1606144 | 6480464 | Doxorubicin results in decreased expression of ZNF827 mRNA | CTD | PMID:29803840 | folic acid | multiple interactions | ISO | RGD:1558203 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ZFP827 gene | CTD | PMID:20938992 | folic acid | decreases expression | ISO | RGD:1606144 | 6480464 | Folic Acid results in decreased expression of ZNF827 mRNA | CTD | PMID:21867686 | formaldehyde | increases expression | ISO | RGD:1606144 | 6480464 | Formaldehyde results in increased expression of ZNF827 mRNA | CTD | PMID:23649840 | gallic acid | decreases expression | ISO | RGD:1606144 | 6480464 | Gallic Acid results in decreased expression of ZNF827 mRNA | CTD | PMID:34408198 | L-methionine | multiple interactions | ISO | RGD:1558203 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ZFP827 gene | CTD | PMID:20938992 | lead diacetate | multiple interactions | ISO | RGD:1606144 | 6480464 | [lead acetate co-treated with zinc protoporphyrin] results in increased expression of ZNF827 mRNA | CTD | PMID:22839698 | lenalidomide | multiple interactions | ISO | RGD:1606144 | 6480464 | lenalidomide results in increased degradation of and results in decreased expression of ZNF827 protein | CTD | PMID:30067223 | Licochalcone B | decreases expression | ISO | RGD:1606144 | 6480464 | licochalcone B results in decreased expression of ZNF827 mRNA | CTD | PMID:33647349 | manganese(II) chloride | increases expression | EXP | | 6480464 | manganese chloride results in increased expression of ZFP827 mRNA | CTD | PMID:28801915 | methotrexate | increases expression | ISO | RGD:1606144 | 6480464 | Methotrexate results in increased expression of ZNF827 mRNA | CTD | PMID:24449571 | N,N-diethyl-m-toluamide | multiple interactions | EXP | | 6480464 | [Permethrin co-treated with DEET] results in decreased methylation of ZFP827 gene | CTD | PMID:33148267 | nickel atom | decreases expression | ISO | RGD:1606144 | 6480464 | Nickel results in decreased expression of ZNF827 mRNA | CTD | PMID:24768652, PMID:25583101 | panobinostat | multiple interactions | ISO | RGD:1606144 | 6480464 | (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ZNF827 mRNA], panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ZNF827 mRNA] | CTD | PMID:26733615 | panobinostat | affects expression | ISO | RGD:1606144 | 6480464 | panobinostat affects the expression of ZNF827 mRNA | CTD | PMID:26733615 | paracetamol | decreases expression | ISO | RGD:1606144 | 6480464 | Acetaminophen results in decreased expression of ZNF827 mRNA | CTD | PMID:22230336 | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of ZFP827 mRNA | CTD | PMID:33387578 | pentanal | decreases expression | ISO | RGD:1606144 | 6480464 | pentanal results in decreased expression of ZNF827 mRNA | CTD | PMID:26079696 | permethrin | multiple interactions | EXP | | 6480464 | [Permethrin co-treated with DEET] results in decreased methylation of ZFP827 gene | CTD | PMID:33148267 | potassium chromate | multiple interactions | ISO | RGD:1606144 | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF827 mRNA | CTD | PMID:22079256 | potassium chromate | decreases expression | ISO | RGD:1606144 | 6480464 | potassium chromate(VI) results in decreased expression of ZNF827 mRNA | CTD | PMID:22079256, PMID:22714537 | S-(1,2-dichlorovinyl)-L-cysteine | decreases expression | ISO | RGD:1606144 | 6480464 | S-(1, 2-dichlorovinyl)cysteine results in decreased expression of ZNF827 mRNA | CTD | PMID:35811015 | SB 431542 | multiple interactions | ISO | RGD:1606144 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF827 mRNA | CTD | PMID:27188386 | silicon dioxide | decreases expression | ISO | RGD:1606144 | 6480464 | Silicon Dioxide analog results in decreased expression of ZNF827 mRNA | CTD | PMID:25895662 | silicon dioxide | increases expression | ISO | RGD:1606144 | 6480464 | Silicon Dioxide results in increased expression of ZNF827 mRNA | CTD | PMID:34973136 | sodium arsenite | increases expression | ISO | RGD:1606144 | 6480464 | sodium arsenite results in increased expression of ZNF827 mRNA | CTD | PMID:29301061 | temozolomide | increases expression | ISO | RGD:1606144 | 6480464 | Temozolomide results in increased expression of ZNF827 mRNA | CTD | PMID:31758290 | titanium dioxide | increases expression | ISO | RGD:1558203 | 6480464 | titanium dioxide results in increased expression of ZFP827 mRNA | CTD | PMID:29264374 | urethane | decreases expression | ISO | RGD:1606144 | 6480464 | Urethane results in decreased expression of ZNF827 mRNA | CTD | PMID:28818685 | valproic acid | affects expression | ISO | RGD:1606144 | 6480464 | Valproic Acid affects the expression of ZNF827 mRNA | CTD | PMID:25979313 | valproic acid | multiple interactions | ISO | RGD:1606144 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF827 mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | RGD:1606144 | 6480464 | Valproic Acid results in decreased expression of ZNF827 mRNA | CTD | PMID:23179753 more ... | zinc protoporphyrin | multiple interactions | ISO | RGD:1606144 | 6480464 | [lead acetate co-treated with zinc protoporphyrin] results in increased expression of ZNF827 mRNA | CTD | PMID:22839698 | zoledronic acid | increases expression | ISO | RGD:1606144 | 6480464 | zoledronic acid results in increased expression of ZNF827 mRNA | CTD | PMID:24714768 | |